LTRN

Lantern Pharma Inc. (LTRN) Business Model Analysis (2026)

Invetso Score: 2/10 — Weak · Last Updated: 2026-09-01

Overall Score

Revenue Model

No meaningful revenue base is evident in the TTM metrics, with revenue per share at 0 and price-to-sales at 0.

The business remains unprofitable, with net profit margin, EBIT margin, and EBITDA margin all at 0 in the provided ratios.

Profitability

TTM returns remain deeply negative, including ROA of -2.17%, ROE of -4.56%, and ROIC of -3.58%.

Operating profitability is still negative, with operating return on assets at -1.95% and EBITDA/EBIT margins at 0.

Balance Sheet

Liquidity is acceptable, with a current ratio of 1.96 and cash ratio of 1.54.

Leverage appears low on a market-cap basis, with debt-to-assets at 0.46% and debt-to-market-cap at 0.16%, though equity and book value remain negative.

Cash Flow

Cash generation is still negative, with operating cash flow per share at -1.13 and free cash flow per share at -1.13.

Cash flow yields remain negative, including free cash flow yield of -0.57% and operating cash flow ratio of -3.26.

Valuation

Traditional valuation multiples are not meaningful or remain distorted, with negative P/E, negative price-to-book, and negative enterprise value multiples.

The market is still pricing the company at a very small enterprise value of about $18.0M versus a market cap of about $24.6M, but this reflects distress rather than clear undervaluation.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Lantern Pharma Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →